Cencora (COR) Stock Forecast & Price Target

$248.40 +4.17 (+1.71%)

(As of 11/26/2024 ET)

Cencora - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
0

Hold
3

Buy
8

Based on 11 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 3 have given a hold rating, and 8 have given a buy rating for COR.

Consensus Price Target

$271.20
9.18% Upside

According to the 11 analysts' twelve-month price targets for Cencora, the average price target is $271.20. The highest price target for COR is $292.00, while the lowest price target for COR is $224.00. The average price target represents a forecasted upside of 9.18% from the current price of $248.40.

Get the Latest News and Ratings for COR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cencora and its competitors.

COR Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)	8 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$271.20	$259.44	$258.63	$197.36
Forecasted Upside	9.18% Upside	10.65% Upside	9.38% Upside	-2.19% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Trump won. Buy this coin now. (Ad)

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

COR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

COR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cencora Stock vs. The Competition

Type	Cencora	Medical Companies	S&P 500
Consensus Rating Score	2.73	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	9.18% Upside	24,786.99% Upside	6.79% Upside
News Sentiment Rating	Positive News See Recent COR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/7/2024	Robert W. Baird 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$287.00 ➝ $292.00	+17.29%
11/7/2024	UBS Group 4 of 5 stars		Boost Target	Buy ➝ Buy	$275.00 ➝ $285.00	+14.68%
11/7/2024	Barclays 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$263.00 ➝ $290.00	+18.18%
11/7/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$250.00 ➝ $285.00	+16.15%
10/7/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$277.00 ➝ $275.00	+25.03%
9/18/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Neutral	$275.00 ➝ $245.00	+4.46%
JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad) Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late.
8/21/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$280.00 ➝ $287.00	+20.03%
8/1/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$236.00 ➝ $249.00	+3.96%
4/30/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$265.00 ➝ $280.00	+16.87%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/5/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$192.00 ➝ $224.00	-4.63%
8/7/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$205.00 ➝ $215.00	+15.07%
8/3/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$176.00 ➝ $190.00	-1.69%
5/26/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/3/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$174.00 ➝ $182.00	+8.81%
1/12/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$170.00 ➝ $190.00	+14.88%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:23 PM ET.

Should I Buy Cencora Stock? COR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, November 24, 2024. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

Cencora
Bull Case

Here are some ways that investors could benefit from investing in Cencora, Inc.:

The current stock price of Cencora, Inc. is $244.60, which reflects a positive trend in the market and indicates potential for growth.
Recent upgrades from multiple analysts, including UBS Group and Barclays, have raised target prices significantly, suggesting strong confidence in the company's future performance.
Cencora, Inc. has increased its quarterly dividend to $0.55 per share, up from $0.51, which indicates a commitment to returning value to shareholders and reflects financial health.
The company has a market capitalization of $48.20 billion, which positions it as a significant player in the pharmaceutical distribution sector, providing stability and growth potential.
With a consensus rating of "Moderate Buy" from analysts, there is a general optimism about the stock's performance, which can attract more investors.

Cencora
Bear Case

Investors should be bearish about investing in Cencora, Inc. for these reasons:

The company has a high debt-to-equity ratio of 4.84, indicating that it relies heavily on debt financing, which can be risky if market conditions change.
Despite recent positive developments, the stock has seen fluctuations, with a one-year low of $195.83, suggesting volatility that could deter risk-averse investors.
Insider selling activity, such as the recent sale of 21,509 shares by the chairman, may raise concerns about the company's future prospects from those within the organization.
The current dividend yield of 0.90% is relatively low compared to other investment opportunities, which may not attract income-focused investors.
Analysts have mixed ratings, with some maintaining a "hold" rating, indicating uncertainty about the stock's short-term performance.

COR Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $271.20, with a high forecast of $292.00 and a low forecast of $224.00.
: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" COR shares.
: According to analysts, Cencora's stock has a predicted upside of 9.18% based on their 12-month stock forecasts.
: Cencora has been rated by research analysts at Bank of America, Barclays, Evercore ISI, Leerink Partners, Robert W. Baird, and UBS Group in the past 90 days.
: Analysts like Cencora less than other "medical" companies. The consensus rating score for Cencora is 2.73 while the average consensus rating score for "medical" companies is 2.80. Learn more on how COR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

This page (NYSE:COR) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cencora (COR) Stock Forecast & Price Target